Laura Chico Analyst Performance

Managing Director, Equity Research at Wedbush

Laura Chico is a stock analyst at Wedbush focused in the medical sector, covering 36 publicly traded companies. Over the past year, Laura Chico has issued 36 stock ratings, including buy and hold recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 65 Last 7 Years
Buy Recommendations: 75.38% 49 Buy Ratings
Companies Covered: 36 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	75.4%	49 ratings
Hold	23.1%	15 ratings
Sell	1.5%	1 ratings

Out of 65 total stock ratings issued by Laura Chico at Wedbush, the majority (75.4%) have been Buy recommendations, followed by 23.1% Hold and 1.5% Sell.

Best & Worst Calls

Best Call
000.0%
BHVN
Jan 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
VTL
Dec 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.9% of companies on NASDAQ	32 companies
NYSE	8.3% of companies on NYSE	3 companies
OTCMKTS	2.8% of companies on OTCMKTS	1 company

Laura Chico, an analyst at Wedbush, currently covers 36 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 34 companies	94.4%
	Construction 1 company	2.8%
	Computer and Technology 1 company	2.8%

Laura Chico of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Construction and Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 24 companies	66.7%
PHARMACEUTICAL PREPARATIONS 5 companies	13.9%
MED - DRUGS 4 companies	11.1%
BLDG - RSDNT/COMR 1 company	2.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.8%
BUSINESS SOFTWARE SERVICES/BPO 1 company	2.8%

About Laura Chico

Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
DNTH Dianthus Therapeutics	9/12/2025	Boost Price Target	$37.86	$44.00	Outperform
TRML Tourmaline Bio	9/9/2025	Downgrade	$30.18	$48.00	Neutral
DNTH Dianthus Therapeutics	8/21/2025	Boost Price Target	$23.72	$42.00	Outperform
JBIO Jade Biosciences	8/14/2025	Boost Price Target	$7.03	$18.00	Outperform
SLDB Solid Biosciences	8/13/2025	Lower Price Target	$6.15	$14.00	Outperform
STOK Stoke Therapeutics	8/13/2025	Boost Price Target	$15.66	$22.00	Outperform
XENE Xenon Pharmaceuticals	8/12/2025	Boost Price Target	$36.10	$43.00	Outperform
TVTX Travere Therapeutics	8/7/2025	Boost Price Target	$17.24	$32.00	Outperform
GOSS Gossamer Bio	8/6/2025	Boost Price Target	$1.97	$5.00	Outperform
ARDX Ardelyx	8/5/2025	Reiterated Rating	$5.08	$14.00	Outperform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
NBIX Neurocrine Biosciences	7/31/2025	Boost Price Target	$136.76	$141.00	Outperform
RARE Ultragenyx Pharmaceutical	7/14/2025	Lower Price Target	$29.51	$34.00	Neutral
MAZE Maze Therapeutics	7/8/2025	Initiated Coverage	$12.12	$17.00	Outperform
LRMR Larimar Therapeutics	6/24/2025	Lower Price Target	$2.76	$15.00	Outperform
LEN Lennar	6/18/2025	Reiterated Rating	$105.15	$130.00	Neutral
BIIB Biogen	6/12/2025	Reiterated Rating	$132.63	$121.00	Neutral
PHVS Pharvaris	6/5/2025	Reiterated Rating	$16.88	$27.00	Outperform
VIGL Vigil Neuroscience	5/22/2025	Downgrade	$2.31	$8.00	Hold
TVTX Travere Therapeutics	5/16/2025	Reiterated Rating	$17.51	$30.00	Outperform
GOSS Gossamer Bio	5/16/2025	Reiterated Rating	$1.08	$4.00	Outperform
ANRO Alto Neuroscience	5/15/2025	Reiterated Rating	$2.26	$4.00	Neutral
DNLI Denali Therapeutics	5/7/2025	Lower Price Target	$14.02	$30.00	Outperform
VERA Vera Therapeutics	5/7/2025	Lower Price Target	$22.33	$26.00	Neutral
VIGL Vigil Neuroscience	5/5/2025	Reiterated Rating	$2.85	$13.00	Outperform
TVTX Travere Therapeutics	5/2/2025	Reiterated Rating	$20.56	$30.00	Outperform
EWTX Edgewise Therapeutics	4/21/2025	Reiterated Rating	$13.67	$43.00	Outperform
VIGL Vigil Neuroscience	3/14/2025	Lower Price Target	$2.15	$13.00	Outperform
GOSS Gossamer Bio	3/14/2025	Reiterated Rating	$1.35	$4.00	Outperform
OVID Ovid Therapeutics	3/12/2025	Reiterated Rating	$0.49	$3.00	Outperform
ATXS Astria Therapeutics	3/12/2025	Reiterated Rating	$6.47	$28.00	Outperform
DNTH Dianthus Therapeutics	3/12/2025	Reiterated Rating	$22.69	$36.00	Outperform
TRML Tourmaline Bio	3/6/2025	Initiated Coverage	$12.90	$42.00	Outperform
APLS Apellis Pharmaceuticals	3/3/2025	Lower Price Target	$25.15	$29.00	Neutral
SAGE Sage Therapeutics	2/12/2025	Reiterated Rating	$7.24	$6.00	Neutral
NBIX Neurocrine Biosciences	2/7/2025	Lower Price Target	$121.12	$147.00	Outperform
RARE Ultragenyx Pharmaceutical	1/13/2025	Reiterated Rating	$41.84	$48.00	Neutral

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.